论文部分内容阅读
Pedersen—Bjergaard等(1991年)报告,用含有足叶乙甙(etoposide)方案治疗胚胎细胞肿瘤可以增高骨髓发育不良和白血病的危险。本文作者所在单位曾把足叶乙甙作为继顺氯氨铂/环磷酰胺/表柔比星(epirubicin)之后的第二线药物(n=31)或继顺氯氨铂/环磷酰胺及单用卡铂(carboplatin)之后的第三线药物(n=14)来治疗45例卵巢上皮癌病人,无1例接受高电压放疗。足叶乙甙平均累积剂量为3200mg/m~2(665～6800mg/m~2)。始用该药后的生存期范围在2～51个月之
Pedersen-Bjergaard et al. (1991) reported that the treatment of embryonal cell tumors with etoposide regimen may increase the risk of myelodysplasia and leukemia. The authors of this study have used etoposide as a second-line drug (n = 31) following cisplatin / cyclophosphamide / epirubicin or cisplatin / cyclophosphamide Forty-five patients with epithelial ovarian cancer were treated with the third-line drug (n = 14) after carboplatin, none of whom received high-voltage radiation. Etoposide average cumulative dose of 3200mg / m ~ 2 (665 ~ 6800mg / m ~ 2). The initial use of the drug after the survival period in the 2 to 51 months